Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients
This study has been terminated.
Information provided by:
First received: December 12, 2006
Last updated: December 15, 2006
Last verified: December 2006
To compare versus placebo the efficacy and safety of recombinant Bet v1, natural purified Bet v1 and birch pollen licenced extract used for subcutaneous immunotherapy.
Biological: Subcutaneous immunotherapy - Recombinant birch pollen
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Double-Blind Placebo-Controlled Study of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients|
Further study details as provided by Stallergenes:
Contacts and Locations